08:06 AM EDT, 07/11/2024 (MT Newswires) -- CureVac ( CVAC ) on Thursday provided the latest trial dates for its ongoing patent litigation against Pfizer ( PFE ) and BioNTech (BNTX) in multiple locations including the US, UK and Germany.

The US trial will take place on March 3, 2025 before the US District Court of the Eastern District of Virginia. A previous court recommendation to stay the proceedings for all 10 US patents was withdrawn, the company said.

Litigation in Europe will continue March 25, 2025, with a hearing on the validity of EP 3 708 668 B1 before the Opposition Division of the European Patent Office. The infringement action related to this patent was suspended pending the validity determination by the European Patent Office, the company said.

Lastly, a trial in the UK started on July 10 based on a declaration of non-infringement and request for revocation by Pfizer ( PFE ) and BioNTech in the UK for the two CureVac ( CVAC ) patents EP 3 708 668 B1 and EP 4 023 755 B1. CureVac ( CVAC ) counterclaimed for infringement and a judgement is expected later in 2024.

Price: 3.1500, Change: +0.04, Percent Change: +1.29